|
1
|
Bast RC Jr: Molecular approaches to
personalizing management of ovarian cancer. Ann Oncol. 2(Suppl 8):
viii5–viii1. 2011.
|
|
2
|
Sun Y, Campisi J, Higano C, Beer TM,
Porter P, Coleman I, True L and Nelson PS: Treatment-induced damage
to the tumor microenvironment promotes prostate cancer therapy
resistance through WNT16B. Nat Med. 18:1359–1368. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yi EH, Lee CS, Lee JK, Lee YJ, Shin MK,
Cho CH, Kang KW, Lee JW, Han W, Noh DY, et al: STAT3-RANTES
autocrine signaling is essential for tamoxifen resistance in human
breast cancer cells. Mol Cancer Res. 11:31–42. 2013. View Article : Google Scholar
|
|
4
|
Velasco-Velázquez M, Jiao X, De La Fuente
M, Pestell TG, Ertel A, Lisanti MP and Pestell RG: CCR5 antagonist
blocks metastasis of basal breast cancer cells. Cancer Res.
72:3839–3850. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luboshits G, Shina S, Kaplan O, Engelberg
S, Nass D, Lifshitz-Mercer B, Chaitchik S, Keydar I and Ben-Baruch
A: Elevated expression of the CC chemokine regulated on activation,
normal T cell expressed and secreted (RANTES) in advanced breast
carcinoma. Cancer Res. 59:4681–4687. 1999.PubMed/NCBI
|
|
6
|
Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki
Y and Abe A: Correlation of tissue and plasma RANTES levels with
disease course in patients with breast or cervical cancer. Clin
Cancer Res. 7:285–289. 2001.PubMed/NCBI
|
|
7
|
Zhang Y, Yao F, Yao X, Yi C, Tan C, Wei L
and Sun S: Role of CCL5 in invasion, proliferation and proportion
of CD44+/ CD24− phenotype of MCF-7 cells and
correlation of CCL5 and CCR5 expression with breast cancer
progression. Oncol Rep. 21:1113–1121. 2009.PubMed/NCBI
|
|
8
|
Jiao X, Katiyar S, Willmarth NE, Liu M, Ma
X, Flomenberg N, Lisanti MP and Pestell RG: c-Jun induces mammary
epithelial cellular invasion and breast cancer stem cell expansion.
J Biol Chem. 285:8218–8226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Karnoub AE, Dash AB, Vo AP, Sullivan A,
Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R and Weinberg
RA: Mesenchymal stem cells within tumour stroma promote breast
cancer metastasis. Nature. 449:557–563. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bromberg J and Darnell JE Jr: The role of
STATs in transcriptional control and their impact on cellular
function. Oncogene. 19:2468–2473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Diaz N, Minton S, Cox C, Bowman T, Gritsko
T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, et al:
Activation of stat3 in primary tumors from high-risk breast cancer
patients is associated with elevated levels of activated SRC and
survivin expression. Clin Cancer Res. 12:20–28. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Johnston PA and Grandis JR: STAT3
signaling: Anticancer strategies and challenges. Mol Interv.
11:18–26. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhong Z, Wen Z and Darnell JE Jr: Stat3: A
STAT family member activated by tyrosine phosphorylation in
response to epidermal growth factor and interleukin-6. Science.
264:95–98. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fukada T, Hibi M, Yamanaka Y,
Takahashi-Tezuka M, Fujitani Y, Yamaguchi T, Nakajima K and Hirano
T: Two signals are necessary for cell proliferation induced by a
cytokine receptor gp130: Involvement of STAT3 in anti-apoptosis.
Immunity. 5:449–460. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bowman T, Garcia R, Turkson J and Jove R:
STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kube D, Holtick U, Vockerodt M, Ahmadi T,
Haier B, Behrmann I, Heinrich PC, Diehl V and Tesch H: STAT3 is
constitutively activated in Hodgkin cell lines. Blood. 98:762–770.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sheng WJ, Jiang H, Wu DL and Zheng JH:
Early responses of the STAT3 pathway to platinum drugs are
associated with cisplatin resistance in epithelial ovarian cancer.
Braz J Med Biol Res. 46:650–658. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Han Z, Feng J, Hong Z, Chen L, Li W, Liao
S, Wang X, Ji T, Wang S, Ma D, et al: Silencing of the STAT3
signaling pathway reverses the inherent and induced chemoresistance
of human ovarian cancer cells. Biochem Biophys Res Commun.
435:188–194. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang CY, Fong YC, Lee CY, Chen MY, Tsai
HC, Hsu HC and Tang CH: CCL5 increases lung cancer migration via
PI3K, Akt and NF-kappaB pathways. Biochem Pharmacol. 77:794–803.
2009. View Article : Google Scholar
|
|
20
|
Asselin E, Mills GB and Tsang BK: XIAP
regulates Akt activity and caspase-3-dependent cleavage during
cisplatin-induced apoptosis in human ovarian epithelial cancer
cells. Cancer Res. 61:1862–1868. 2001.PubMed/NCBI
|
|
21
|
Navab R, Strumpf D, Bandarchi B, Zhu CQ,
Pintilie M, Ramnarine VR, Ibrahimov E, Radulovich N, Leung L,
Barczyk M, et al: Prognostic gene-expression signature of
carcinoma-associated fibroblasts in non-small cell lung cancer.
Proc Natl Acad Sci USA. 108:7160–7165. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weng D, Song X, Xing H, Ma X, Xia X, Weng
Y, Zhou J, Xu G, Meng L, Zhu T, et al: Implication of the
Akt2/survivin pathway as a critical target in paclitaxel treatment
in human ovarian cancer cells. Cancer Lett. 273:257–265. 2009.
View Article : Google Scholar
|
|
23
|
Sun C, Li N, Yang Z, Zhou B, He Y, Weng D,
Fang Y, Wu P, Chen P, Yang X, et al: miR-9 regulation of BRCA1 and
ovarian cancer sensitivity to cisplatin and PARP inhibition. J Natl
Cancer Inst. 105:1750–1758. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cole SP, Bhardwaj G, Gerlach JH, Mackie
JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM and
Deeley RG: Overexpression of a transporter gene in a
multidrug-resistant human lung cancer cell line. Science.
258:1650–1654. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kruh GD and Belinsky MG: The MRP family of
drug efflux pumps. Oncogene. 22:7537–7552. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Seike T, Fujita K, Yamakawa Y, Kido MA,
Takiguchi S, Teramoto N, Iguchi H and Noda M: Interaction between
lung cancer cells and astrocytes via specific inflammatory
cytokines in the microenvironment of brain metastasis. Clin Exp
Metastasis. 28:13–25. 2011. View Article : Google Scholar :
|
|
28
|
Wang D, Yamamoto S, Hijiya N, Benveniste
EN and Gladson CL: Transcriptional regulation of the human
osteopontin promoter: Functional analysis and DNA-protein
interactions. Oncogene. 19:5801–5809. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rath BH, Fair JM, Jamal M, Camphausen K
and Tofilon PJ: Astrocytes enhance the invasion potential of
glioblastoma stem-like cells. PLoS One. 8:e547522013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu L, Nam S, Tian Y, Yang F, Wu J, Wang
Y, Scuto A, Polychronopoulos P, Magiatis P, Skaltsounis L, et al:
6-Bromoindirubin-3′-oxime inhibits JAK/STAT3 signaling and induces
apoptosis of human melanoma cells. Cancer Res. 71:3972–3979. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Karar J and Maity A: PI3K/AKT/mTOR pathway
in angiogenesis. Front Mol Neurosci. 4:512011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang HY, Zhang PN and Sun H: Aberration
of the PI3K/AKT/ mTOR signaling in epithelial ovarian cancer and
its implication in cisplatin-based chemotherapy. Eur J Obstet
Gynecol Reprod Biol. 146:81–86. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tang CH, Yamamoto A, Lin YT, Fong YC and
Tan TW: Involvement of matrix metalloproteinase-3 in CCL5/CCR5
pathway of chondrosarcomas metastasis. Biochem Pharmacol.
79:209–217. 2010. View Article : Google Scholar
|
|
34
|
Wang SW, Wu HH, Liu SC, Wang PC, Ou WC,
Chou WY, Shen YS and Tang CH: CCL5 and CCR5 interaction promotes
cell motility in human osteosarcoma. PLoS One. 7:e351012012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Eissa SA, Zaki SA, El-Maghraby SM and
Kadry DY: Importance of serum IL-18 and RANTES as markers for
breast carcinoma progression. J Egypt Natl Canc Inst. 17:51–55.
2005.PubMed/NCBI
|
|
36
|
Kim HK, Song KS, Park YS, Kang YH, Lee YJ,
Lee KR, Kim HK, Ryu KW, Bae JM and Kim S: Elevated levels of
circulating platelet microparticles, VEGF, IL-6 and RANTES in
patients with gastric cancer: possible role of a metastasis
predictor. Eur J Cancer. 39:184–191. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tsukishiro S, Suzumori N, Nishikawa H,
Arakawa A and Suzumori K: Elevated serum RANTES levels in patients
with ovarian cancer correlate with the extent of the disorder.
Gynecol Oncol. 102:542–545. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ostman A: The tumor microenvironment
controls drug sensitivity. Nat Med. 18:1332–1334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bruchard M, Mignot G, Derangère V, Chalmin
F, Chevriaux A, Végran F, Boireau W, Simon B, Ryffel B, Connat JL,
et al: Chemotherapy-triggered cathepsin B release in
myeloid-derived suppressor cells activates the Nlrp3 inflammasome
and promotes tumor growth. Nat Med. 19:57–64. 2013. View Article : Google Scholar
|
|
40
|
Wilson TR, Fridlyand J, Yan Y, Penuel E,
Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, et al:
Widespread potential for growth-factor-driven resistance to
anticancer kinase inhibitors. Nature. 487:505–509. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Straussman R, Morikawa T, Shee K,
Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J,
Frederick DT, et al: Tumour micro-environment elicits innate
resistance to RAF inhibitors through HGF secretion. Nature.
487:500–504. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Benabbou N, Mirshahi P, Cadillon M, Soria
J, Therwath A and Mirshahi M: Hospicells promote upregulation of
the ATP-binding cassette genes by insulin-like growth factor-I via
the JAK2/STAT3 signaling pathway in an ovarian cancer cell line.
Int J Oncol. 43:685–694. 2013.PubMed/NCBI
|
|
43
|
Kim JE, Kim HS, Shin YJ, Lee CS, Won C,
Lee SA, Lee JW, Kim Y, Kang JS, Ye SK, et al: LYR71, a derivative
of trimeric resveratrol, inhibits tumorigenesis by blocking
STAT3-mediated matrix metalloproteinase 9 expression. Exp Mol Med.
40:514–522. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ji T, Gong D, Han Z, Wei X, Yan Y, Ye F,
Ding W, Wang J, Xia X, Li F, et al: Abrogation of constitutive
Stat3 activity circumvents cisplatin resistant ovarian cancer.
Cancer Lett. 341:231–239. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Aoki Y, Feldman GM and Tosato G:
Inhibition of STAT3 signaling induces apoptosis and decreases
survivin expression in primary effusion lymphoma. Blood.
101:1535–1542. 2003. View Article : Google Scholar
|
|
46
|
Real PJ, Sierra A, De Juan A, Segovia JC,
Lopez-Vega JM and Fernandez-Luna JL: Resistance to chemotherapy via
Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer
cells. Oncogene. 21:7611–7618. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cao Y: Opinion: Emerging mechanisms of
tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer.
5:735–743. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Rasila KK, Burger RA, Smith H, Lee FC and
Verschraegen C: Angiogenesis in gynecological oncology-mechanism of
tumor progression and therapeutic targets. Int J Gynecol Cancer.
15:710–726. 2005. View Article : Google Scholar : PubMed/NCBI
|
